Replies to post #146844 on Biotech Values

[mcbio]

The reason I have to believe that there will be CRs is that in the last update, the CEO mentioned there were several patients still receiving maintenance therapy of bavituximab. This is only allowed under the trial design if disease has not progressed. All, IMO.

If a patient had a CR, they wouldn't need to still receive maintenance therapy of bavi. And just because the disease hasn't progressed doesn't mean a CR is forthcoming.